论文部分内容阅读
目的探讨联合检测中晚期非小细胞肺癌(NSCLC)患者血清癌胚抗原(CEA)、癌抗原125(CA125)和血管内皮生长因子(VEGF)在化疗疗效评估中的价值。方法采用ELISA和免疫放射分析法测定45例中晚期NSCLC患者(肺癌组)化疗前、后血清CEA、CA125和VEGF的水平;以45例健康者为对照组。结果肺癌组血清CEA、CA125和VEGF明显高于对照组(P<0.05);肺癌组CEA、CA125和VEGF在化疗后均低于化疗前(P<0.05)。结论血清CEA、CA125和VEGF水平与肺癌病情变化相关。联合检测血清CEA、CA125和VEGF对评估中晚期NSCLC患者病情及预后有一定的参考价值。
Objective To investigate the value of combined detection of serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125) and vascular endothelial growth factor (VEGF) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Serum levels of CEA, CA125 and VEGF in 45 patients with advanced non-small cell lung cancer (NSCLC) before and after chemotherapy were measured by ELISA and immuno-radiometric assay, and 45 healthy controls were used as control. Results The serum levels of CEA, CA125 and VEGF in lung cancer group were significantly higher than those in control group (P <0.05). The levels of CEA, CA125 and VEGF in lung cancer group were lower than those before chemotherapy after chemotherapy (P <0.05). Conclusion Serum levels of CEA, CA125 and VEGF are correlated with the changes of lung cancer. Combined detection of serum CEA, CA125 and VEGF in the evaluation of advanced NSCLC patients with disease and prognosis of a certain reference value.